Lafayette General Health’s research department is seeking male and female pancreatic cancer patients for an observational study on the impact of chemotherapy on their quality of life.

Survey participants must be 18 or older. The study will evaluate the medications Abraxane and Gemcitabine in patients diagnosed with metastatic adenocarcinoma of the pancreas.

“The objective of the research is to gather information and assess the quality of life in patients who are newly diagnosed before initiation of first-line chemotherapy, or currently treated with certain medications. Patients may have a stable disease or be failing one or more rounds of chemotherapy,” hospital officials said in a news release. “Through a one-time online survey, LGH’s Research Department will assess the impact of chemotherapy regimens by measuring a patient’s physical health, pain, psychological health, physical limitations, social activities or disease-specific items.”

For more information on this and other clinical trials available through Lafayette General Health, call (337) 289-8658 or visit LafayetteGeneral.com/ClinicalTrials.